RFK Jr. Says 14 Peptides Are Returning to Legal Compounding — Here's What's Real
-
Big news dropped on February 27, 2026 — RFK Jr. went on Joe Rogan and said roughly 14 of the 19 peptides the FDA restricted back in 2023 are being moved back to Category 1 status. That would mean licensed compounding pharmacies can prepare them again under a physician's prescription.
The 14 reportedly coming back include BPC-157, TB-500, Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, Selank, Semax, KPV, MOTS-C, GHK-Cu, and a few others.
The 5 that are staying restricted: Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF.
Now here's where I want to pump the brakes a little, because I'm seeing a lot of people misread what this actually means right now.
No formal FDA rule has been published yet. The PCAC review meeting is scheduled for July 23–24, 2026 — that's when formal implementation is supposed to move forward. So legally, we're still in a transitional gray zone until that happens. None of these compounds have FDA approval. A physician prescription is still required for any compounded version. And honestly, the quality verification piece matters more now than ever — unregulated sellers are already using RFK's statements as cover to push products with zero quality oversight.
The direction is encouraging, but implementation is still pending. COA standards haven't changed just because someone made an announcement on a podcast.
Curious where others are at with this — has this news shifted how you're thinking about your research planning, or are you holding off until the formal rule actually gets published?
-
It's wild that someone with zero relevant background or qualifications can end up in a position that literally requires deep analytical and scientific knowledge — that's a pretty glaring gap in the system. There really should be stronger requirements that disqualify people who lack the foundational education for roles like this. This whole situation just exposes how loose the entry criteria are, and honestly it's scary to think it could happen again with someone even less qualified down the road.
-
Honestly the joke's on everyone making a big deal out of this — some of us have been sourcing from underground labs this whole time and never stopped.
-
Honestly, I'd love to see him shift some of that energy toward figuring out why ALS rates seem to be climbing instead of fixating on the things he usually goes after.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Register Login